14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications.
14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications.
复制标题
14,15-氯氧基-5,8,11-三烯酸(14,15-EET)替代物:羧酸盐修饰。
DOI:
10.1021/jm500262m
复制
发表时间:
2014-08-28
影响因子:
7.3
通讯作者:
Campbell WB
中科院分区:
文献类型:
--
作者:
Falck JR;Koduru SR;Mohapatra S;Manne R;Atcha KR;Atcha R;Manthati VL;Capdevila JH;Christian S;Imig JD;Campbell WB
The cytochrome P450 eicosanoid 14,15-epoxyeicosa-5,8,11-trienoic acid (14,15-EET) is a powerful endogenous autacoid that has been ascribed an impressive array of physiologic functions including regulation of blood pressure. Because 14,15-EET is chemically and metabolically labile, structurally related surrogates containing epoxide bioisosteres were introduced and have become useful in vitro pharmacologic tools but are not suitable for in vivo applications. A new generation of EET mimics incorporating modifications to the carboxylate were prepared and evaluated for vasorelaxation and inhibition of soluble epoxide hydrolase (sEH). Tetrazole 19 (ED50 0.18 μM) and oxadiazole-5-thione 25 (ED50 0.36 μM) were 12- and 6-fold more potent, respectively, than 14,15-EET as vasorelaxants; on the other hand, their ability to block sEH differed substantially, i.e., 11 vs >500 nM. These data will expedite the development of potent and specific in vivo drug candidates.
登录
查看更多内容
DOI:
10.1152/ajpheart.00831.2001
发表时间:
2003-01-01
影响因子:
4.8
作者:
Falck, JR;Krishna, UM;Campbell, WB
通讯作者:
Campbell, WB
影响因子:
9.3
作者:
Gauthier, KM;Falck, JR;Campbell, WB
通讯作者:
Campbell, WB
影响因子:
5
作者:
Deng Y;Theken KN;Lee CR
通讯作者:
Lee CR
DOI:
10.1152/ajpheart.00448.2002
发表时间:
2002-12-01
影响因子:
4.8
作者:
Fang, X;Weintraub, NL;Spector, AA
通讯作者:
Spector, AA
影响因子:
2.9
作者:
Fang, X;Weintraub, NL;Spector, AA
通讯作者:
Spector, AA